1. Home
  2. CRNX

as 10-07-2025 3:29pm EST

$
-
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.

Founded: 2008 Country:
United States
United States
Employees: N/A City: SAN DIEGO
Market Cap: 2.8B IPO Year: 2018
Target Price: $74.45 AVG Volume (30 days): 1.9M
Analyst Decision: Buy Number of Analysts: 12
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -4.12 EPS Growth: N/A
52 Week Low/High: $24.10 - $62.53 Next Earning Date: 11-11-2025
Revenue: $1,392,000 Revenue Growth: 0.51%
Revenue Growth (this year): 469.59% Revenue Growth (next year): 705.27%

Stock Insider Trading Activity of Crinetics Pharmaceuticals Inc. (CRNX)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Pizzuti Dana CRNX Chief Med and Dev Officer Oct 1 '25 Sell $41.81 5,000 $209,050.00 66,270
Struthers Richard Scott CRNX President & CEO Sep 26 '25 Sell $45.00 4,000 $180,000.00 106,000
Fust Matthew K CRNX Director Sep 26 '25 Sell $44.75 16,000 $716,000.00 22,836
Pizzuti Dana CRNX Chief Med and Dev Officer Sep 2 '25 Sell $32.10 5,000 $160,500.00 66,270
Pizzuti Dana CRNX Chief Med and Dev Officer Aug 22 '25 Sell $30.43 30,000 $912,900.00 66,270
Pizzuti Dana CRNX Chief Med and Dev Officer Aug 20 '25 Sell $29.18 6,492 $189,436.56 66,270

Share on Social Networks: